Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date: December 16, 2025
Subject: Announcement of topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA clinical trial for alopecia areata.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details the results of the global Phase 2b study involving 92 patients with severe-to-very-severe alopecia areata. Patients were randomized to receive rezpegaldesleukin (24 µg/kg or 18 µg/kg) or placebo.
- Primary Endpoint (Mean % SALT Reduction at Week 36):
- Full Analysis (mITT): The primary endpoint narrowly missed statistical significance. Reductions were 28.2% (24 µg/kg, p=0.186) and 30.3% (18 µg/kg, p=0.121) versus 11.2% for placebo.
- Analysis Excluding Eligibility Violations: Four patients had major eligibility violations. When excluded, both dose arms met statistical significance. Reductions were 29.6% (24 µg/kg, p=0.049) and 30.4% (18 µg/kg, p=0.042) versus 5.7% for placebo.
- Secondary Endpoints: Both dose arms showed dose-dependent effects compared to placebo on SALT ≥ 30% reduction, SALT ≤ 30, SALT ≤ 20, and SALT ≤ 10. The study was not powered for statistical significance on secondary endpoints.
- Safety Profile: Favorable safety and tolerability observed. Discontinuation rate due to adverse events was 1.4% in combined treatment arms. No increased risk of major adverse cardiovascular events, thrombosis, infection, acne, or oral herpes compared to placebo.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- The Company plans to submit REZOLVE-AA results for presentation at a medical conference in 2026.
- Data from the 16-week treatment extension (Week 52) will be available in early Q2 2026.
- Rezpegaldesleukin remains an investigational agent with a high risk of failure prior to regulatory approval.
- Forward-looking statements regarding timing and therapeutic potential are subject to risks including regulatory delays, manufacturing challenges, and competitive factors.
- The filing explicitly states that the Company undertakes no obligation to update the materials attached.
Investor Verification Checklist
- Verify the impact of the four patients with major eligibility violations on the statistical significance of the primary endpoint.
- Review the full safety data regarding injection site reactions (ISRs) and long-term tolerability from the 52-week extension data when available in Q2 2026.
- Confirm the specific medical conference and date for the 2026 data presentation.
- Assess the company's cash runway and capital requirements for advancing the program, as this 8-K does not provide financial liquidity data.